Concepts (186)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Autistic Disorder | 14 | 2020 | 44 | 2.840 |
Why?
|
| Anticonvulsants | 7 | 2025 | 9 | 1.630 |
Why?
|
| Seizures | 5 | 2025 | 16 | 1.580 |
Why?
|
| Epilepsy | 9 | 2026 | 14 | 1.510 |
Why?
|
| Diazepam | 1 | 2025 | 3 | 0.910 |
Why?
|
| Child | 21 | 2026 | 524 | 0.890 |
Why?
|
| Child, Preschool | 19 | 2023 | 258 | 0.870 |
Why?
|
| Humans | 32 | 2026 | 6794 | 0.740 |
Why?
|
| Quinidine | 1 | 2020 | 1 | 0.650 |
Why?
|
| Dopamine Antagonists | 1 | 2020 | 1 | 0.650 |
Why?
|
| Dextromethorphan | 1 | 2020 | 2 | 0.650 |
Why?
|
| Blood Transfusion, Autologous | 1 | 2018 | 2 | 0.550 |
Why?
|
| Umbilical Cord | 1 | 2018 | 9 | 0.550 |
Why?
|
| Stem Cells | 1 | 2018 | 19 | 0.550 |
Why?
|
| Fetal Blood | 1 | 2018 | 41 | 0.550 |
Why?
|
| Adolescent | 12 | 2026 | 869 | 0.540 |
Why?
|
| Autism Spectrum Disorder | 1 | 2018 | 23 | 0.530 |
Why?
|
| Male | 23 | 2025 | 3671 | 0.530 |
Why?
|
| Electroencephalography | 4 | 2006 | 17 | 0.500 |
Why?
|
| Child Development Disorders, Pervasive | 3 | 2007 | 8 | 0.480 |
Why?
|
| Adult | 12 | 2026 | 2113 | 0.470 |
Why?
|
| Female | 19 | 2025 | 4060 | 0.460 |
Why?
|
| Treatment Outcome | 9 | 2025 | 500 | 0.460 |
Why?
|
| Double-Blind Method | 5 | 2022 | 101 | 0.420 |
Why?
|
| Infant | 9 | 2023 | 187 | 0.410 |
Why?
|
| Autoimmune Diseases | 2 | 2010 | 9 | 0.380 |
Why?
|
| Young Adult | 6 | 2025 | 567 | 0.360 |
Why?
|
| Lennox Gastaut Syndrome | 2 | 2023 | 2 | 0.350 |
Why?
|
| Cannabidiol | 2 | 2023 | 3 | 0.350 |
Why?
|
| Immunotherapy | 1 | 2010 | 16 | 0.330 |
Why?
|
| Valproic Acid | 3 | 2006 | 4 | 0.320 |
Why?
|
| Cross-Over Studies | 2 | 2020 | 27 | 0.300 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2009 | 4 | 0.300 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2009 | 5 | 0.300 |
Why?
|
| Clonidine | 1 | 2009 | 3 | 0.300 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2009 | 19 | 0.290 |
Why?
|
| Databases, Factual | 1 | 2009 | 81 | 0.290 |
Why?
|
| Pyridones | 2 | 2025 | 3 | 0.280 |
Why?
|
| Polysomnography | 2 | 2006 | 2 | 0.270 |
Why?
|
| Encephalitis | 1 | 2007 | 6 | 0.260 |
Why?
|
| Memantine | 1 | 2007 | 2 | 0.260 |
Why?
|
| Sleep Wake Disorders | 2 | 2004 | 16 | 0.260 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2007 | 9 | 0.260 |
Why?
|
| Drug Therapy, Combination | 3 | 2025 | 84 | 0.260 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2007 | 48 | 0.260 |
Why?
|
| Middle Aged | 5 | 2025 | 2108 | 0.250 |
Why?
|
| Transition to Adult Care | 1 | 2026 | 23 | 0.240 |
Why?
|
| Nasal Sprays | 1 | 2025 | 1 | 0.230 |
Why?
|
| Administration, Intranasal | 1 | 2025 | 4 | 0.230 |
Why?
|
| Communication Disorders | 1 | 2004 | 1 | 0.220 |
Why?
|
| Preservatives, Pharmaceutical | 1 | 2004 | 1 | 0.220 |
Why?
|
| Thimerosal | 1 | 2004 | 1 | 0.220 |
Why?
|
| Self-Injurious Behavior | 1 | 2004 | 8 | 0.220 |
Why?
|
| Anxiety Disorders | 1 | 2004 | 7 | 0.220 |
Why?
|
| Immunization | 1 | 2004 | 19 | 0.220 |
Why?
|
| Aggression | 2 | 2020 | 9 | 0.220 |
Why?
|
| Depressive Disorder | 1 | 2004 | 28 | 0.220 |
Why?
|
| Consensus | 1 | 2024 | 39 | 0.210 |
Why?
|
| Carbamates | 1 | 2004 | 1 | 0.210 |
Why?
|
| Phenylcarbamates | 1 | 2004 | 1 | 0.210 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2004 | 2 | 0.210 |
Why?
|
| Status Epilepticus | 2 | 2024 | 4 | 0.200 |
Why?
|
| Retrospective Studies | 4 | 2022 | 681 | 0.200 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2004 | 82 | 0.200 |
Why?
|
| Compassionate Use Trials | 1 | 2023 | 3 | 0.200 |
Why?
|
| Carnosine | 1 | 2002 | 1 | 0.190 |
Why?
|
| Neuroprotective Agents | 1 | 2002 | 14 | 0.190 |
Why?
|
| Brain | 5 | 2019 | 94 | 0.190 |
Why?
|
| 4-Aminopyridine | 1 | 2020 | 1 | 0.170 |
Why?
|
| Vesicle-Associated Membrane Protein 2 | 1 | 2020 | 1 | 0.170 |
Why?
|
| Irritable Mood | 1 | 2020 | 1 | 0.160 |
Why?
|
| Secretin | 1 | 2000 | 13 | 0.160 |
Why?
|
| Mutation | 1 | 2020 | 97 | 0.160 |
Why?
|
| Pilot Projects | 1 | 2020 | 89 | 0.160 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2019 | 2 | 0.150 |
Why?
|
| Receptors, AMPA | 1 | 2019 | 3 | 0.150 |
Why?
|
| Intellectual Disability | 1 | 2019 | 7 | 0.150 |
Why?
|
| Drug Resistant Epilepsy | 1 | 2019 | 1 | 0.150 |
Why?
|
| Epilepsies, Myoclonic | 1 | 2019 | 1 | 0.150 |
Why?
|
| Primates | 1 | 2018 | 2 | 0.140 |
Why?
|
| Arginine Vasopressin | 1 | 2018 | 46 | 0.140 |
Why?
|
| Landau-Kleffner Syndrome | 3 | 2005 | 3 | 0.140 |
Why?
|
| Aged | 3 | 2025 | 1539 | 0.130 |
Why?
|
| Infant, Newborn | 2 | 2009 | 199 | 0.120 |
Why?
|
| Autoantibodies | 3 | 2005 | 12 | 0.120 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2007 | 16 | 0.110 |
Why?
|
| Monitoring, Ambulatory | 2 | 2006 | 5 | 0.110 |
Why?
|
| Risk Factors | 2 | 2010 | 767 | 0.110 |
Why?
|
| Animals | 4 | 2018 | 1875 | 0.110 |
Why?
|
| Immunoglobulin G | 4 | 2005 | 19 | 0.110 |
Why?
|
| Phenytoin | 1 | 1994 | 1 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2004 | 63 | 0.110 |
Why?
|
| Brain Diseases | 1 | 1994 | 3 | 0.110 |
Why?
|
| Nitriles | 2 | 2025 | 13 | 0.100 |
Why?
|
| Follow-Up Studies | 2 | 2007 | 268 | 0.100 |
Why?
|
| Biomarkers | 2 | 2018 | 214 | 0.090 |
Why?
|
| Social Behavior | 2 | 2018 | 14 | 0.090 |
Why?
|
| Meningitis | 1 | 1989 | 2 | 0.080 |
Why?
|
| Ibuprofen | 1 | 1989 | 4 | 0.080 |
Why?
|
| Injections, Intravenous | 2 | 2000 | 19 | 0.080 |
Why?
|
| Central Nervous System | 1 | 2007 | 8 | 0.070 |
Why?
|
| Early Diagnosis | 1 | 2007 | 26 | 0.070 |
Why?
|
| Aged, 80 and over | 1 | 2009 | 497 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 118 | 0.060 |
Why?
|
| Nervous System | 1 | 2005 | 2 | 0.060 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2005 | 3 | 0.060 |
Why?
|
| Nervous System Diseases | 2 | 1999 | 7 | 0.060 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2004 | 1 | 0.050 |
Why?
|
| Complementary Therapies | 1 | 2004 | 11 | 0.050 |
Why?
|
| Vitamins | 1 | 2004 | 14 | 0.050 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2004 | 10 | 0.050 |
Why?
|
| Outpatients | 1 | 2024 | 10 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2024 | 16 | 0.050 |
Why?
|
| Rivastigmine | 1 | 2004 | 1 | 0.050 |
Why?
|
| Pattern Recognition, Visual | 1 | 2004 | 1 | 0.050 |
Why?
|
| Vocabulary | 1 | 2004 | 2 | 0.050 |
Why?
|
| Language Development Disorders | 1 | 2004 | 2 | 0.050 |
Why?
|
| Acetylcholine | 1 | 2004 | 4 | 0.050 |
Why?
|
| Reference Values | 1 | 2004 | 56 | 0.050 |
Why?
|
| Personality Assessment | 1 | 2004 | 6 | 0.050 |
Why?
|
| Neuropsychological Tests | 1 | 2004 | 15 | 0.050 |
Why?
|
| Cognition Disorders | 1 | 2004 | 19 | 0.050 |
Why?
|
| Siblings | 1 | 2004 | 7 | 0.050 |
Why?
|
| Disease Progression | 1 | 2024 | 170 | 0.050 |
Why?
|
| Patient Safety | 1 | 2023 | 10 | 0.050 |
Why?
|
| Fucose | 1 | 1983 | 1 | 0.050 |
Why?
|
| Myelin Sheath | 1 | 1983 | 1 | 0.050 |
Why?
|
| Sciatic Nerve | 1 | 1983 | 1 | 0.050 |
Why?
|
| Leucine | 1 | 1983 | 2 | 0.050 |
Why?
|
| Diabetic Neuropathies | 1 | 1983 | 3 | 0.050 |
Why?
|
| Myelin Proteins | 1 | 1983 | 4 | 0.050 |
Why?
|
| Triazoles | 1 | 2023 | 12 | 0.050 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 1983 | 29 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2019 | 285 | 0.050 |
Why?
|
| United States | 1 | 2026 | 1019 | 0.050 |
Why?
|
| Synaptic Vesicles | 1 | 2020 | 1 | 0.040 |
Why?
|
| Synaptic Transmission | 1 | 2020 | 4 | 0.040 |
Why?
|
| Exocytosis | 1 | 2020 | 4 | 0.040 |
Why?
|
| Electrophysiology | 1 | 2020 | 8 | 0.040 |
Why?
|
| Metronidazole | 1 | 2000 | 3 | 0.040 |
Why?
|
| Crohn Disease | 1 | 2000 | 5 | 0.040 |
Why?
|
| Anti-Infective Agents | 1 | 2000 | 9 | 0.040 |
Why?
|
| Magnetoencephalography | 1 | 1999 | 1 | 0.040 |
Why?
|
| Loss of Function Mutation | 1 | 2019 | 1 | 0.040 |
Why?
|
| Heterozygote | 1 | 2019 | 9 | 0.040 |
Why?
|
| Diarrhea | 1 | 2019 | 10 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 64 | 0.040 |
Why?
|
| Mental Disorders | 1 | 2000 | 60 | 0.040 |
Why?
|
| Macaca mulatta | 1 | 2018 | 8 | 0.040 |
Why?
|
| Mice | 2 | 1994 | 746 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2018 | 246 | 0.030 |
Why?
|
| Electroshock | 1 | 1994 | 1 | 0.030 |
Why?
|
| Drug Synergism | 1 | 1994 | 26 | 0.030 |
Why?
|
| Drug Interactions | 1 | 1994 | 27 | 0.030 |
Why?
|
| Myoclonus | 1 | 1993 | 1 | 0.030 |
Why?
|
| Ocular Motility Disorders | 1 | 1993 | 1 | 0.030 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1993 | 25 | 0.030 |
Why?
|
| Antibodies, Antinuclear | 2 | 2005 | 3 | 0.020 |
Why?
|
| Immunoglobulin M | 2 | 2005 | 6 | 0.020 |
Why?
|
| Cerebral Cortex | 2 | 2005 | 15 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2005 | 118 | 0.020 |
Why?
|
| Penicillin G | 1 | 1989 | 1 | 0.020 |
Why?
|
| Spinal Nerve Roots | 1 | 1989 | 1 | 0.020 |
Why?
|
| Cerebrospinal Fluid | 1 | 1989 | 2 | 0.020 |
Why?
|
| Arthritis, Infectious | 1 | 1988 | 3 | 0.020 |
Why?
|
| Mycoses | 1 | 1988 | 5 | 0.020 |
Why?
|
| Myelin Basic Protein | 1 | 2005 | 2 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 2005 | 3 | 0.010 |
Why?
|
| Histones | 1 | 2005 | 13 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 35 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2005 | 17 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2005 | 234 | 0.010 |
Why?
|
| Carbon Radioisotopes | 1 | 1983 | 3 | 0.010 |
Why?
|
| Tritium | 1 | 1983 | 4 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 1983 | 10 | 0.010 |
Why?
|
| Sleep | 1 | 1999 | 14 | 0.010 |
Why?
|
| Temporal Lobe | 1 | 1999 | 4 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1993 | 26 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 1993 | 25 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 1993 | 31 | 0.010 |
Why?
|
| Acremonium | 1 | 1988 | 1 | 0.000 |
Why?
|
| Knee Joint | 1 | 1988 | 1 | 0.000 |
Why?
|
| Synovial Fluid | 1 | 1988 | 2 | 0.000 |
Why?
|
| Knee Injuries | 1 | 1988 | 4 | 0.000 |
Why?
|
| Wounds, Penetrating | 1 | 1988 | 9 | 0.000 |
Why?
|
| Acute Disease | 1 | 1988 | 91 | 0.000 |
Why?
|